IZZO, BARBARA
IZZO, BARBARA
Istituto di Biostrutture e Bioimmagini - IBB - Sede Napoli
FLT3 MUTATIONS IN MLL-REARRANGED INFANT ACUTE LYMPHOBLASIC LEUKEMIA (ALL): EXPERIENCE OF A SINGLE PEDIATRIC INSTITUTION
2010 Parasole, R; Petruzziello, F; Izzo, B; Parasole, R; Casadei, Gm; Farina, V; Menna, G; Maisto, G; Mangione, A; Pane, F; Poggi, V
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients
2010 Esposito, N; Quintarelli, C; Colavita, I; Izzo, B; Peluso, AL; Ruoppolo, M; Del Vecchio, L; Russo, D; Branford, S; Iacobucci, I; Thornquist, M; Barnett, M; Melo, J; Saglio, G; Radich, J; Peter, L; Martinelli, G; Kalebic, T; Hughes, T; Pane, F
A decreased Level of Shp1 provides an additive survival advantage to the Ph plus Cells of CML Patients and may account for Resistance to Imatinib Treatment
2009 Esposito, N; Colavita, I; Quarantelli, F; Izzo, B; Luciano, L; Del Vecchio, L; Hughes, T; Radich, J; Russo, D; Soverini, S; Iacobucci, I; Martinelli, G; Saglio, G; Melo, J; Ruoppolo, M; Kalebic, T; Pane, F
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
2009 Cilloni, D; Renneville, A; Hermitte, F; Hills, Rk; Daly, S; Jovanovic, Jv; Gottardi, E; Fava, M; Schnittger, S; Weiss, T; Izzo, B; Nomdedeu, J; van der Heijden, A; van der Reijden, B A; Jansen, J H; van der Velden, V H; Ommen, H; Preudhomme, C; Saglio, G; Grimwade, D
REDUCED LEVELS OF SHP1 PROVIDES AN ADDITIVE SURVIVAL ADVANTAGE TO THE PH+ CELLS OF CML PATIENTS AND MAY ACCOUNT FOR RESISTANCE TO IMA TREATMENT
2009 Esposito, N; Colavita, I; Izzo, B; Quarantelli, F; Sica, Ra; Buonomo, T; Roberti, V; Luciano, L; Del Vecchio, L; Peluso, A; Melo, Jv; Russo, D; Martinelli, G; Martinelli, R; Ruoppolo, M; Pane, F
The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial
2009 Esposito, N; Quarantelli, F; Luciano, L; Izzo, B; Peluso, Al; Picardi, M; Branford, S; White, Dl; Hughes, T; Radich, J; Soverini, S; Iacobucci, I; Saglio, G; Kalebic, T; Thomquist, M; Martinelli, G; Pane, F
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
2008 Lococo, F; Cuneo, A; Pane, F; Cilloni, D; Diverio, D; Mancini, M; Testoni, N; Bardi, A; Izzo, B; Bolli, N; La Starza, R; Fazi, P; Lacobelli, S; Piciocchi, A; Vignetti, M; Amadori, S; Mandelli, F; Pelicci, Pg; Mecucci, C; Falini, B; Saglio, G
Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype
2007 Palmieri S; Ferrara F; Leoni F; Ciolli S; Pollio F; D'Amico MR; Celentano M; Viola A; Vicari L; Izzo B; Pane F.
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
2006 Iacobucci, I; Saglio, G; Rosti, G; Testoni, N; Pane, F; Amabile, M; Poerio, A; Soverini, S; Bassi, S; Cilloni, D; Bassan, R; Breccia, M; Lauria, F; Izzo, B; Marente, S; Frassoni, F; Paolini, S; Montefusco, E; Baccarini, M; Martinelli, G; Ginema Working, Party
Contribution of ABL kinase domain mutation to imatinib resistance in different subsets of Philadelphia-positive patients: by the GINEMA working party on Chronic Myeloid Leukemia
2006 Soverini, S; Colarossi, S; Gnani, A; Rosti, G; Castagnetti, F; Poerio, A; Iacobucci, I; Amabile, M; Abruzzese, E; Orlandi, E; Radaelli, F; Ciccone, F; Tirimbelli, M; Di Lorenzo, R; Caracciolo, C; Izzo, B; Pane, F; Saglio, G; Baccarini, M; Martinelli, G; Ginema workin, Party
Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia
2006 Ferrara, F; Palmieri, S; Pollio, F; Lo Pardo, C; Graziano, D; Celentano, M; D'Amico, Mr; Vicari, L; Izzo, B; Pane, F
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of pregression to blast crisis and shorter survilval: a study by the GIMEMA Working Party
2005 Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; De Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarini M.
Significant reduction of the hybrid BCR/ABL transcripts after inducyion and consolidation therapy is a powerful predictor of tratmnt response in adult Philadelphia-positive acute lymbophoblastic leukemia
2005 Pane, F; Cimino, G; Izzo, B; Camera, A; Vitale, A; Quintarelli, C; Picardi, M; Specchia, G; Mancini, M; Cuneo, A; Mecucci, C; Martinelli, G; Saglio, G; Rotoli, B; Mandelli, F; Salvatore, F; Foa, R; Gimema, Group
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
2004 Michele Baccarani; Giovanni Martinelli; Gianantonio Rosti; Elena Trabacchi; Nicoletta Testoni; Simona Bassi; Marilina Amabile; Simona Soverini; Fausto Castagnetti; Daniela Cilloni; Barbara Izzo; Antonio de Vivo; Emanuela Messa; Francesca Bonifazi; Angela Poerio; Simona Luatti; Emilia Giugliano; Daniele Alberti; Gianluca Fincato; Domenico Russo; Fabrizio Pane; Giuseppe Saglio;for the GIMEMA Working Party on Chronic Myeloid Leukemia
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| FLT3 MUTATIONS IN MLL-REARRANGED INFANT ACUTE LYMPHOBLASIC LEUKEMIA (ALL): EXPERIENCE OF A SINGLE PEDIATRIC INSTITUTION | 1-gen-2010 | Parasole, R; Petruzziello, F; Izzo, B; Parasole, R; Casadei, Gm; Farina, V; Menna, G; Maisto, G; Mangione, A; Pane, F; Poggi, V | |
| Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients | 1-gen-2010 | Esposito, N; Quintarelli, C; Colavita, I; Izzo, B; Peluso, AL; Ruoppolo, M; Del Vecchio, L; Russo, D; Branford, S; Iacobucci, I; Thornquist, M; Barnett, M; Melo, J; Saglio, G; Radich, J; Peter, L; Martinelli, G; Kalebic, T; Hughes, T; Pane, F | |
| A decreased Level of Shp1 provides an additive survival advantage to the Ph plus Cells of CML Patients and may account for Resistance to Imatinib Treatment | 1-gen-2009 | Esposito, N; Colavita, I; Quarantelli, F; Izzo, B; Luciano, L; Del Vecchio, L; Hughes, T; Radich, J; Russo, D; Soverini, S; Iacobucci, I; Martinelli, G; Saglio, G; Melo, J; Ruoppolo, M; Kalebic, T; Pane, F | |
| Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study | 1-gen-2009 | Cilloni, D; Renneville, A; Hermitte, F; Hills, Rk; Daly, S; Jovanovic, Jv; Gottardi, E; Fava, M; Schnittger, S; Weiss, T; Izzo, B; Nomdedeu, J; van der Heijden, A; van der Reijden, B A; Jansen, J H; van der Velden, V H; Ommen, H; Preudhomme, C; Saglio, G; Grimwade, D | |
| REDUCED LEVELS OF SHP1 PROVIDES AN ADDITIVE SURVIVAL ADVANTAGE TO THE PH+ CELLS OF CML PATIENTS AND MAY ACCOUNT FOR RESISTANCE TO IMA TREATMENT | 1-gen-2009 | Esposito, N; Colavita, I; Izzo, B; Quarantelli, F; Sica, Ra; Buonomo, T; Roberti, V; Luciano, L; Del Vecchio, L; Peluso, A; Melo, Jv; Russo, D; Martinelli, G; Martinelli, R; Ruoppolo, M; Pane, F | |
| The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial | 1-gen-2009 | Esposito, N; Quarantelli, F; Luciano, L; Izzo, B; Peluso, Al; Picardi, M; Branford, S; White, Dl; Hughes, T; Radich, J; Soverini, S; Iacobucci, I; Saglio, G; Kalebic, T; Thomquist, M; Martinelli, G; Pane, F | |
| Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia | 1-gen-2008 | Lococo, F; Cuneo, A; Pane, F; Cilloni, D; Diverio, D; Mancini, M; Testoni, N; Bardi, A; Izzo, B; Bolli, N; La Starza, R; Fazi, P; Lacobelli, S; Piciocchi, A; Vignetti, M; Amadori, S; Mandelli, F; Pelicci, Pg; Mecucci, C; Falini, B; Saglio, G | |
| Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype | 1-gen-2007 | Palmieri S; Ferrara F; Leoni F; Ciolli S; Pollio F; D'Amico MR; Celentano M; Viola A; Vicari L; Izzo B; Pane F. | |
| Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients | 1-gen-2006 | Iacobucci, I; Saglio, G; Rosti, G; Testoni, N; Pane, F; Amabile, M; Poerio, A; Soverini, S; Bassi, S; Cilloni, D; Bassan, R; Breccia, M; Lauria, F; Izzo, B; Marente, S; Frassoni, F; Paolini, S; Montefusco, E; Baccarini, M; Martinelli, G; Ginema Working, Party | |
| Contribution of ABL kinase domain mutation to imatinib resistance in different subsets of Philadelphia-positive patients: by the GINEMA working party on Chronic Myeloid Leukemia | 1-gen-2006 | Soverini, S; Colarossi, S; Gnani, A; Rosti, G; Castagnetti, F; Poerio, A; Iacobucci, I; Amabile, M; Abruzzese, E; Orlandi, E; Radaelli, F; Ciccone, F; Tirimbelli, M; Di Lorenzo, R; Caracciolo, C; Izzo, B; Pane, F; Saglio, G; Baccarini, M; Martinelli, G; Ginema workin, Party | |
| Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia | 1-gen-2006 | Ferrara, F; Palmieri, S; Pollio, F; Lo Pardo, C; Graziano, D; Celentano, M; D'Amico, Mr; Vicari, L; Izzo, B; Pane, F | |
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of pregression to blast crisis and shorter survilval: a study by the GIMEMA Working Party | 1-gen-2005 | Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; De Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarini M. | |
| Significant reduction of the hybrid BCR/ABL transcripts after inducyion and consolidation therapy is a powerful predictor of tratmnt response in adult Philadelphia-positive acute lymbophoblastic leukemia | 1-gen-2005 | Pane, F; Cimino, G; Izzo, B; Camera, A; Vitale, A; Quintarelli, C; Picardi, M; Specchia, G; Mancini, M; Cuneo, A; Mecucci, C; Martinelli, G; Saglio, G; Rotoli, B; Mandelli, F; Salvatore, F; Foa, R; Gimema, Group | |
| Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. | 1-gen-2004 | Michele Baccarani; Giovanni Martinelli; Gianantonio Rosti; Elena Trabacchi; Nicoletta Testoni; Simona Bassi; Marilina Amabile; Simona Soverini; Fausto Castagnetti; Daniela Cilloni; Barbara Izzo; Antonio de Vivo; Emanuela Messa; Francesca Bonifazi; Angela Poerio; Simona Luatti; Emilia Giugliano; Daniele Alberti; Gianluca Fincato; Domenico Russo; Fabrizio Pane; Giuseppe Saglio;for the GIMEMA Working Party on Chronic Myeloid Leukemia |